What Does ABPI Have To Say About NICE Proposals?

Catchpole welcomes the concept put forth in these new NICE proposals on value based assessment criteria, but says it’s too early to understand the full impact they will have on future medicines access. Read more here. (Source: FirstWord Pharma, 1/10/14).

You might also be interested in:

Gottlieb’s Full Statement on New FDA Efforts to Prop… June 14, 2018
Trump White House Defends Plan to Cut Drug Prices May 15, 2018
CVS Caremark’s Foray into Cost-Effectiveness Analysis… September 25, 2018
Time to Market: Accelerating Market Access January 4, 2019
ICER Using New Economic Modeling Platform for Value Assessment August 24, 2018
Transitioning Payment Models: Fee-for-Service to Value-Based Care November 16, 2018
Orphan Drugs: European Payer Perspectives October 14, 2018